## Prescriber Criteria Form

## Cotellic 2024 PA Fax 1307-A v2 010124.docx Cotellic (cobimetinib) Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**.

Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process.

When conditions are met, we will authorize the coverage of Cotellic (cobimetinib).

Drug Name:

Cotellic (cobimetinib)

Patie	nt Name:			
Patie	nt ID:			
Patient DOB:		ent Phone:		
Preso	criber Name:			
Preso	criber Address:			
City:		e: Zip:		
Prescriber Phone: Diagnosis:		scriber Fax:		
		ICD Code(s):		
Plea	ase circle the appropriate answer for each question	on.		
1	Does the patient have a diagnosis of melanoma? [If yes, then skip to question 6.]	?	Yes	No
2	Does the patient have a diagnosis of central nerv	vous system (CNS) cancer?	Yes	No
3	Is the patient diagnosed with one of following: A) D) oligodendroglioma? [If no, then no further questions.]	glioma, B) glioblastoma, C) astrocytoma,	Yes	No
4	Does the patient have disease that is positive for Please select 'No' if unknown. [If no, then no further questions.]	BRAF V600E activating mutation?	Yes	No
5	Will the requested drug be used in combination v [No further questions.]	with vemurafenib?	Yes	No
6	Will the requested medication be used for the adjuvant treatment of melanoma? [If yes, then skip to question 8.]		Yes	No
7	Does the patient have unresectable, limited rese [If no, then no further questions.]	ctable, or metastatic disease?	Yes	No

Prescr	iber (or Authorized) Signature: Date:		<del></del>
	ning this form, I attest that the information provided is accurate and true as of this date and that entation supporting this information is available for review if requested by the health plan.	at the	
Comm	ents:		
11	Will the requested drug be used as a single agent?	Yes	No
	[If no, then no further questions.]		
10	Does the patient have a diagnosis of histiocytic neoplasm?	Yes	No
	[No further questions.]		
9	Will the requested drug be used in combination with vemurafenib?	Yes	No
	[If no, then no further questions.]		
	BRAF V600E or V600K mutation)? Please select 'No' if unknown.		
8	Does the patient have disease that is positive for a BRAF V600 activating mutation (e.g.,	Yes	No